Skip to main content

Table 2 Pharmacological characteristics of BDP and FF administered as monocomponents on the histaminergic contractile tone of medium bronchi and small airways (PCLS) in non-sensitized and passively sensitized tissues

From: Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways

 

BDP

FF

Medium bronchi

Bronchioles

Medium bronchi

Bronchioles

Emax

pEC50

Emax

pEC50

Emax

pEC50

Emax

pEC50

Non-sensitized

< 20%

NC

< 20%

NC

97.00 ± 2.77%

8.26 ± 0.07

72.03% ± 4.34#

7.13 ± 0.11#

Passively sensitized

< 20%

NC

< 20%

NC

94.96 ± 1.22%

8.89 ± 0.04***

105.30%***

7.52 ± 0.09*#

  1. *P < 0.05 and ***P < 0.001 vs. non-sensitized airways of equal diameter, #P < 0.001 vs. medium bronchi undergoing the same treatment (statistical significance assessed by t-test). BDP Beclomethasone dipropionate, EC50 The concentration inducing 50% EmaxE max maximal effect, FF Formoterol fumarate, NC Not calculable, PCLS Precision cut lung slices, pEC 50 -LogEC50